What other information should I know?
Keep all appointments with your doctor and the laboratory.
Before having any laboratory test, tell your doctor and the laboratory personnel that you are using mesalamine.
Do not let anyone else use your medication. Ask your pharmacist any questions you have about refilling your prescription.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
What are some things I need to know or do while I take sfRowasa?
- Tell all of your health care providers that you take this medicine. This includes your doctors, nurses, pharmacists, and dentists.
- Avoid driving and doing other tasks or actions that call for you to be alert until you see how sfRowasa affects you.
- Have blood work checked as you have been told by the doctor. Talk with the doctor.
- This medicine may affect certain lab tests. Tell all of your health care providers and lab workers that you take this medicine.
- You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.
- Some males have had sperm problems while taking sfRowasa. This may affect being able to father a child. This may go back to normal after the drug is stopped. Talk with the doctor.
- Use with care in children. Talk with the doctor.
- If you are 65 or older, use this medicine with care. You could have more side effects.
- Do not give to children and teenagers who have or are getting better from flu signs, chickenpox, or other viral infections due to the chance of Reye's syndrome. Reye's syndrome causes very bad problems to the brain and liver.
- This medicine may stain fabric, flooring, painted surfaces, marble, granite, vinyl, and enamel.
- If you are allergic to sulfites, talk with your doctor. Some products have sulfites.
- Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using sfRowasa while you are pregnant.
- Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.
Consumer Information Use and Disclaimer
- If your symptoms or health problems do not get better or if they become worse, call your doctor.
- Do not share your drugs with others and do not take anyone else's drugs.
- Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.
- Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.
- Some drugs may have another patient information leaflet. Check with your pharmacist. If you have any questions about sfRowasa, please talk with your doctor, nurse, pharmacist, or other health care provider.
- If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.
This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about sfRowasa (mesalamine rectal enema). It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using sfRowasa.
Review Date: October 4, 2017